The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company’s main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types.

The University of Arizona Health Network (doing business as Uahealth), a subsidiary of Banner Health, is a company headquartered in Tucson, AZ, specializing in colleges, universities, and professional schools. Banner Health acquired The University of Arizona Health Network on March 02, 2015.

Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish company located in Dublin that manufactures and distributes pharmaceutical products. Salix Pharmaceuticals Ltd., now part of Bausch Health Cos., Inc. acquired Cosmo Technologies Ltd. from Cosmo Pharmaceuticals SA.\nThe company says this about itself: COSMO designs, manufactures and markets family-safe technology products. Committed to the idea that technology should be designed for families, not just repurposed from other segments, COSMO is pioneering new product categories. At the center of its offerings is its mobile application, COSMO: Mission Control. This hub for managing connected devices and family software is meant for families who are seeking a new way of doing technology.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Cell Pathways develops small molecule-based drugs for cancer treatment. The company has developed an apoptosis technology platform for the development of therapeutic agents for cancer. These can be used in combination with other chemotherapy drugs.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Jhpiego has made an effort to save lives all over the world. Together they change health systems and the prospects of families all over the world in a variety of ways including maternal care, men's health, innovations, immunizations, and so much more  they work alongside some of the heroes. Their tales are from the front lines of healthcare in some of the world's most remote and unprotected areas. They strive for larger global family and maternity health and safety. By making a gift to it enable us to provide families worldwide with the quality healthcare they deserve as well as the improved health and futures that come from creating and providing life-saving healthcare solutions in with health practitioners from member states.

Galderma Research & Development SNC discovers, develops, and markets therapeutic, corrective, and aesthetic solutions. The company is headquartered in Biot, France.

Europroteome AG develops diagnostic, immunological, and prognostic tools as well as patient-specific therapies for human epithelial cancers.

SK Telecom Co., Ltd. (Hangul: SK텔레콤 or 에스케이텔레콤) is a South Korean wireless telecommunications operator; it is part of the SK Group, one of the country's largest chaebols. SK Telecom is South Korea's largest wireless carrier: it leads the local market with 50.5 percent share as of 2008. Since its creation in 1984, the company has evolved from a first generation analog cellular system, to second generation CDMA, then to the world's first third-generation synchronized IMT-2000 cellular system. SK Telecom also became the world's first carrier to commercialize HSDPA in May 2006. SK expanded into the landline market by acquiring second-rated fixed-line operator Hanaro Telecom in February 2008.

Since its founding in 2006, Escape Therapeutics has dedicated itself to transforming healthcare through discovery, development, and commercialization of innovative stem cell-based curative therapeutics capable of relieving the suffering of children and adults inflicted with devastating diseases or injuries that are currently inadequately treated and/or incurable.

Wuhan Heer Medical Technology Development Co. Ltd., a subsidiary of Boai NKY Medical Holdings Ltd., is a company headquartered in Wuhan, China, that engages in medical equipment development operation. It was acquired by Boai NKY Medical Holdings Ltd. on November 13, 2014 for $46.72 million.

Beijing Yunhui Pharmaceutical Technology Co., Ltd., established on 2016-09-20, Business scope includes biological,medicine,Health products,chemical industry,Technology development of medical devices,technology transfer,technical consulting,Technical Services;Technology Import and Export,Import and export,Agent import and export;Sales of biological reagents(Does not contain drugs);Medical Science Research and Experimental Development;data processing(limited toPUEvalue in1.5The following cloud computing data);translation service;Conference Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

OncoHealth Corp. operates as a protein biomarker diagnostics company. It commercializes unique proprietary tests for cervical cancer and other cancers associated with human papillomavirus (HPV). The company was founded by Winnie H. Wan and Shuling Cheng in December on July 26, 2010 and is headquartered in Mountain View, CA.

Part of Insmed, Inc., Transave LLC is an American company focused on pharmaceutical preparations.

Ammunition is a biotech company that creates technology for early cancer detection with a focus on endometrial, colorectal, cervical, and esophageal cancer. To help clinicians effectively detect, diagnose, and treat early cancer, the firm conducts research and develops early cancer detection technologies using epigenetics, nanomaterials, bioinformatics, big data technology, and artificial intelligence analysis.

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

DEKK-TEC was formed in 1983, and has utilized government and private funding to effectively develop new therapies and clinical development candidates for the treatment of cancer, pre-cancerous lesions, and women's health issues. We have previously licensed two of our pipeline products to Biotech/Pharmaceutical companies who have successfully driven these compounds into Phase II clinical development. We also have experience with 510K devise submissions. Our present objective is to continue to create and develop new and novel drugs based on our current novel cancer therapeutic agents - DM-CHOC-PEN and hydroperoxy analogs.